JP2018520101A5 - - Google Patents

Info

Publication number

JP2018520101A5

JP2018520101A5 JP2017560213A JP2017560213A JP2018520101A5 JP 2018520101 A5 JP2018520101 A5 JP 2018520101A5 JP 2017560213 A JP2017560213 A JP 2017560213A JP 2017560213 A JP2017560213 A JP 2017560213A JP 2018520101 A5 JP2018520101 A5 JP 2018520101A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

seq

antibody

composition according

amino acid

Prior art date

2016-05-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims description 96
• 238000000034 method Methods 0.000 claims description 87
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
• 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 25
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 22
• 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 21
• 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 21
• 229940079156 Proteasome inhibitor Drugs 0.000 claims description 20
• 239000003207 proteasome inhibitor Substances 0.000 claims description 20
• 239000003246 corticosteroid Substances 0.000 claims description 18
• MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 18
• 108010003272 Hyaluronate lyase Proteins 0.000 claims description 16
• 102000001974 Hyaluronidases Human genes 0.000 claims description 16
• 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 16
• 239000003814 drug Substances 0.000 claims description 16
• 229960002773 hyaluronidase Drugs 0.000 claims description 16
• 229940124597 therapeutic agent Drugs 0.000 claims description 16
• 229960003957 dexamethasone Drugs 0.000 claims description 14
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 14
• 206010002022 amyloidosis Diseases 0.000 claims description 13
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
• 229960001467 bortezomib Drugs 0.000 claims description 12
• 230000000747 cardiac effect Effects 0.000 claims description 12
• 229960004397 cyclophosphamide Drugs 0.000 claims description 12
• 208000021161 Plasma cell disease Diseases 0.000 claims description 10
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
• 229960003648 ixazomib Drugs 0.000 claims description 10
• 229940099039 velcade Drugs 0.000 claims description 10
• 210000004369 blood Anatomy 0.000 claims description 9
• 239000008280 blood Substances 0.000 claims description 9
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 8
• 229940030115 ninlaro Drugs 0.000 claims description 8
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 6
• 208000023761 AL amyloidosis Diseases 0.000 claims description 6
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 6
• BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 6
• 108010021331 carfilzomib Proteins 0.000 claims description 6
• 210000004027 cell Anatomy 0.000 claims description 6
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 6
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 6
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 6
• 229960005184 panobinostat Drugs 0.000 claims description 6
• FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims description 6
• 238000001959 radiotherapy Methods 0.000 claims description 5
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
• 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
• 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 4
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 4
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 4
• 102000006992 Interferon-alpha Human genes 0.000 claims description 4
• 108010047761 Interferon-alpha Proteins 0.000 claims description 4
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
• 208000034578 Multiple myelomas Diseases 0.000 claims description 4
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
• 206010057249 Phagocytosis Diseases 0.000 claims description 4
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
• 230000000735 allogeneic effect Effects 0.000 claims description 4
• 210000004381 amniotic fluid Anatomy 0.000 claims description 4
• 230000006907 apoptotic process Effects 0.000 claims description 4
• 210000001185 bone marrow Anatomy 0.000 claims description 4
• 229960002438 carfilzomib Drugs 0.000 claims description 4
• 238000002512 chemotherapy Methods 0.000 claims description 4
• 230000001419 dependent effect Effects 0.000 claims description 4
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
• 230000000694 effects Effects 0.000 claims description 4
• 201000003444 follicular lymphoma Diseases 0.000 claims description 4
• 102000052645 human CD38 Human genes 0.000 claims description 4
• 229960004942 lenalidomide Drugs 0.000 claims description 4
• 229960001924 melphalan Drugs 0.000 claims description 4
• 230000008782 phagocytosis Effects 0.000 claims description 4
• 210000004180 plasmocyte Anatomy 0.000 claims description 4
• 210000000130 stem cell Anatomy 0.000 claims description 4
• 229960003433 thalidomide Drugs 0.000 claims description 4
• 238000002054 transplantation Methods 0.000 claims description 4
• UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims description 3
• 230000005855 radiation Effects 0.000 claims description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
• 229940098174 alkeran Drugs 0.000 claims description 2
• 201000005787 hematologic cancer Diseases 0.000 claims description 2
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
• 229940000764 kyprolis Drugs 0.000 claims description 2
• 229940008606 pomalyst Drugs 0.000 claims description 2
• 229940120975 revlimid Drugs 0.000 claims description 2
• 229940034915 thalomid Drugs 0.000 claims description 2
• 210000003958 hematopoietic stem cell Anatomy 0.000 claims 2
• 206010028980 Neoplasm Diseases 0.000 claims 1
• 230000036210 malignancy Effects 0.000 claims 1
• -1 pomalimid Chemical compound 0.000 claims 1
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000007717 exclusion Effects 0.000 description 1
• 229960000688 pomalidomide Drugs 0.000 description 1